Aclaris Therapeutics (ACRS) Gains from Investment Securities (2018 - 2025)
Aclaris Therapeutics' (ACRS) quarterly Gains from Investment Securities came in at $400000.0 in Q4 2025, up 130.77% year-on-year from $173333.3 in Q4 2024, and up 300.0% quarter-over-quarter from $100000.0 in Q3 2025.
Aclaris Therapeutics (ACRS) Gains from Investment Securities (2018 - 2025) Analysis & Trends
Aclaris Therapeutics' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $400000.0 for Q4 2025.
- On a quarterly basis, Gains from Investment Securities rose 130.77% year-over-year to $400000.0 in Q4 2025; TTM through Mar 2026 was $2.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.3 million, down 8.0% from the prior year.
- Gains from Investment Securities grew to $400000.0 in Q4 2025 per ACRS's latest filing, from $100000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $16.4 million in Q1 2021 and bottomed at -$26.3 million in Q4 2023.
- The 5-year median for Gains from Investment Securities is $600000.0 (2024), against an average of $346950.0.
- Across the five-year window, Gains from Investment Securities jumped 830.33% in 2021 and tumbled 470.42% in 2023, its largest moves.
- Year by year, Gains from Investment Securities stood at $2.2 million in 2021, then surged by 222.73% to $7.1 million in 2022, then tumbled by 470.42% to -$26.3 million in 2023, then jumped by 95.06% to -$1.3 million in 2024, then surged by 130.77% to $400000.0 in 2025.
- Per Business Quant, the three latest ACRS Gains from Investment Securities figures stand at $400000.0 (Q4 2025), $100000.0 (Q3 2025), and $1.5 million (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Aclaris Therapeutics | 687.20 Mn | 581.79 Mn | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | -1.30 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | -26.30 Mn |
| Dec 31, 2023 | -26.30 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.70 Mn |